LifeNet Health  



The global standard in allograft surgical solutions.

LifeNet Health helps to save lives, restore health and give hope to thousands of patients each year. We are the world’s most trusted provider of transplant solutions, from organ procurement to new innovations in bio-implant technologies and cellular therapies—a leader in the field of regenerative medicine, while always honoring the donors and healthcare professionals that allow the healing process.


 Videos

ViviGen® - Dr. John Hall, Orthopedic Spine Surgeon
VertiGraft® - Dr. Michael Haglund, Neurosurgeon

 Press Releases

  • Virginia Beach, Va. (Oct. 6, 2020) — LifeNet Health will feature its advanced biologic solutions for fusion during the North American Spine Society’s 2020 Annual Meeting, which is being held virtually Oct. 6-9. The global leader in regenerative medicine will spotlight three industry-leading biologics — ViviGen Cellular Bone Matrix, PliaFX moldable demineralized fibers, and VertiGraft structural allografts.

    Attendees can visit LifeNet Health’s presence in the NASS Annual Meeting exhibitor gallery or visit LifeNet Health’s online showcase to learn more about how these solutions support cost-effective care and exceptional patient outcomes.

    Clinically and Economically Proven Solutions
    Among the featured content is recent data that shows ViviGen supports not only effective healing, but also economical care. An analysis of more than 16,000 patients showed that fusions utilizing ViviGen resulted in total hospitalization charges that were nearly 30 percent lower compared to a leading growth factor-based bone graft. In addition, a 2019 study published in the Journal of Orthopedic Surgery Research showed that ViviGen helped achieve a fusion rate of more than 98 percent in complex, multi-level lumbar fusion — results that outperform alternative solutions such as growth factors and autograft.

    “The clinical advantage of ViviGen has been proven by its foundational science and patient outcomes since its debut in 2014,” said Daniel Osborne, Vice President of Global Marketing and Commercial Strategy. “Now, the data emerging tells an economic story that is equally powerful, especially during this unique time in health care.”

    The economic advantage of LifeNet Health implants extends to PliaFX Prime, the world’s most-versatile osteobiologic. PliaFX Prime, a moldable fiber graft, is composed entirely of demineralized cortical fibers, and data shows that 100 percent bone grafts grow more bone than grafts with a carrier.1,2

    Bringing Clarity to the Biologics Landscape
    As a recognized leader in allograft technology, LifeNet Health is uniquely positioned to offer insight that can help both clinicians and materials managers deepen their understanding of biologics. A pre-recorded webinar — “bioLOGIC: Understanding the Bone Void Filler Landscape” — will be available through the Annual Meeting. It provides a high-level overview of bone void filler categories as well as clinical factors that influence the decision of which graft to use. 

    About LifeNet Health
    LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

    1. Boyan BD, Ranly DM, McMillan J, et al. Osteoinductive Ability of Human Allograft Formulations. J Periodontol. September 2006.
    2. Data on file LifeNet Health TR-0446.
  • Virginia Beach, Va. (Oct. 7, 2020) — LifeNet Health has launched VertiGraft ACIS VG2, the first allograft interbody spacer specifically designed for ACIS instrumentation.

    Comprised of a cancellous core and cortical endplates, VertiGraft ACIS VG2 is uniquely engineered to provide mechanical strength, reduce migration, and facilitate early vascularization and bone remodeling.1 It is the latest generation of the VertiGraft portfolio of allograft implants, which have a proven record of clinical effectiveness. A prospective study found 100% fusion rates after 12 months in 74 ACDF patients while facilitating bone growth and remodeling.2

    “VertiGraft ACIS VG2 brings together the latest in structural allograft technology with state-of-the-art spinal instrumentation,” said Heather Pierce, General Manager of Global Spine and General Orthopedics at LifeNet Health. “The result is greater efficiency and flexibility for clinicians and effective healing for patients.”

    The VertiGraft ACIS VG2 allograft is available in multiple footprints, in both parallel and lordotic configurations to optimize fit, fill, and saggital balance restoration. The cortical endplates provide the necessary strength to support the load of the cervical spine, and the cancellous center allows for early bone and vascular in‑growth.1,3 In addition, the chamfered profile is designed for easy insertion. It is processed with LifeNet Health’s Allowash XGâ and Preservonâ technologies, providing the assurance of medical device-grade sterility with the convenience of room-temperature storage.

    About LifeNet Health
    LifeNet Health helps save lives, restore health, and give hope to thousands each year. It is the world's most trusted provider of transplant solutions — from organ procurement to bio-implants and cellular therapies — and a leader in regenerative medicine, while always honoring the donors and healthcare professionals who enable healing. For more information about LifeNet Health, go to www.lifenethealth.org.

    1. Fox B, Gopez A, Sukovich W, and Kerner M. Anterior Cervical Spine Fusion Rates Using a Frozen Laminated Composite Allograft and Plating The Internet Journal of Spine Surgery. 2005; 2(1).
    2. Abla A, El Kadi H, Bost J, Maroon J, and Wert M. Allograft Composite Cortical and Cancellous Bone Graft for Anterior Cervical Fusion. Contemporary Neurosurgery: A Biweekly Publication for Clinical Neurosurgical Continuing Medical Education. 2005;27(8):1-6.
    3. Salter R B. Textbook of Disorders and Injuries of the Musculoskeletal System. 1st ed. Baltimore: Williams & Wilkins; 1970.

 Featured Products

  • ViviGen Cellular Bone Matrix
    ViviGen is the first cellular allograft focused on recovering and protecting lineage-committed bone cells, which are preferred cells for bone formation compared to undifferentiated Mesenchymal Stem Cells (MSCs)....

  • ViviGen® Cellular Bone Matrix represents a paradigm shift in the field of bone repair. A body of evidence has emerged supporting the fact that bone cells are the preferred cells for bone formation compared to undifferentiated Mesenchymal Stem Cells (MSCs), because they are fully differentiated and are committed solely to laying down bone matrix.
  • VertiGraft®
    Innovative allografts, engineered to promote fusion in the treatment of degenerative disease in both lumbar and cervical applications....

  • VertiGraft® ACIS VG2TM
    Comprised of a cancellous core and cortical endplates, the newest allograft implant in the VertiGraft portfolio of solutions is uniquely engineered to provide mechanical strength, reduce migration, and facilitate early vascularization and bone remodeling in accordance with Wolff’s Law.

    • Proven Clinical Performance: The cortical cancellous design optimizes strength and clinical success. A prospective study found 100% fusion rates after 12 months in 74 ACDF Patients.1
    • Osteoconductive: Large cancellous matrix facilitates bone growth and remodeling in accordance with Wolff’s Law.
    • Stability: Textured surface and multiple footprints optimize fit and fill while reducing migration.
    • Sagittal Balance: Available in both neutral and lordotic footprints to reproduce and correct the anatomy.
    • Convenience: Preservon® is a proprietary, glycerol-based preservation technology that allows LifeNet Health allograft implants to be stored in a fully hydrated state at ambient temperature. Lengthy thawing or rehydration time is eliminated with out compromising allograft strength.2
    • Sterile: Sterilized using proprietary and patented Allowash XG® technology. This technology provides a sterility assurance level of 10-6, without compromising the implants inherent osteoconductive properties.3

    References:
    1. Abla A, El Kadi H, Bost J, Maroon J, and Wert M. Allograft Composite Cortical and Cancellous Bone Graft for Anterior Cervical Fusion. Contemporary Neurosurgery: A Biweekly Publication for Clinical Neurosurgical Continuing Medical Education. 2005;27(8):1-6.
    2. Independent sources include Virginia Commonwealth University Medical Center and the American Association of Mechanical Engineers. Data on File at LifeNet Health, Virginia Beach VA.
    3. Eisenlohr LM. “Allograft Tissue Sterilization Using Allowash XG” 2007 BioImplants Brief VG2® Cervical Allograft Spacer and VG1® Cervical Allograft Spacer
  • PliaFX® Prime and Strip
    The PliaFX family of osteobiologics is comprised of 100% bone fibers, demineralized to encourage bone formation and healing. The fibers interlock, allowing the graft to become moldable upon rehydration without the use of a carrier....

    • 100% Cortical Bone: Grows more bone than DBMs containing a carrier, as demonstrated in literature.1
    • Resists Migration: Interlocking fibers allow graft to remain intact and in place.
    • Customizable: PliaFX Prime easily mixes with autograft, allograft, and/or fluid of surgeon’s choice. PliaFX Strip can be cut to size after rehydration to match surgical needs.
    • Convenience: Ambient storage.
    • Osteoconductive: Large surface area and interconnected network of demineralized cortical fibers provides a scaffold that promotes cellular attachment and cell spreading.2,3
    • Osteoinductive Potential: Every lot tested in a rodent model as a final product to ensure osteoinductive potential.
    • Safety: Sterilized using proprietary Allowash XG® technology, providing a sterility assurance level of 10-6 to reduce the risk of disease transmission without compromising the graft’s osteoconductive properties or osteoinductive potential.3,4

    References:

    1. Kay JF, Vaughan LM. Proportional osteoinduction of demineralized bone matrix graft materials. February 2004: AW-0204.1.
    2. Murphy MB, Suzuki RK, Sand TT, et al. Short term culture of mesenchymal stem cells with commercial osteoconductive carriers provides unique insights into biocompatibility. J Clin. Med. 2013; 2,49-66; doi:10.3390/jcm2030049
    3. Data on file LifeNet Health, ES-17-111-02
    4. Eisenlohr LM. “Allograft Tissue Sterilization Using Allowash XG(R).” 2007 Bio-Implants Brief.

Send Email

Type your information and click "Send Email" to send an email to this exhibitor. To return to the previous screen without saving, click "Reset".